Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

63 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Melatonin: A Molecule for Reducing Breast Cancer Risk.
González-González A, Mediavilla MD, Sánchez-Barceló EJ. González-González A, et al. Among authors: sanchez barcelo ej. Molecules. 2018 Feb 6;23(2):336. doi: 10.3390/molecules23020336. Molecules. 2018. PMID: 29415446 Free PMC article. Review.
The effect of estradiol, progesterone, and melatonin on estrous cycling and ovarian aromatase expression in intact female mice.
Bondi CD, Alonso-Gonzalez C, Clafshenkel WP, Kotlarczyk MP, Dodda BR, Sanchez-Barcelo E, Davis VL, Witt-Enderby PA. Bondi CD, et al. Eur J Obstet Gynecol Reprod Biol. 2014 Mar;174:80-5. doi: 10.1016/j.ejogrb.2013.11.027. Epub 2013 Dec 9. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 24373455
Inhibitory effects of melatonin on sulfatase and 17beta-hydroxysteroid dehydrogenase activity and expression in glioma cells.
González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Alvarez-García V, Sánchez-Barceló EJ, Cos S. González A, et al. Oncol Rep. 2010 Apr;23(4):1173-8. doi: 10.3892/or_00000748. Oncol Rep. 2010. PMID: 20204307
Role of melatonin in the epigenetic regulation of breast cancer.
Korkmaz A, Sanchez-Barcelo EJ, Tan DX, Reiter RJ. Korkmaz A, et al. Breast Cancer Res Treat. 2009 May;115(1):13-27. doi: 10.1007/s10549-008-0103-5. Epub 2008 Jul 1. Breast Cancer Res Treat. 2009. PMID: 18592373 Review.
In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin.
González A, Alvarez-García V, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ, Cos S. González A, et al. Curr Cancer Drug Targets. 2010 May;10(3):279-86. doi: 10.2174/156800910791190201. Curr Cancer Drug Targets. 2010. PMID: 20370689
Recent patents on light based therapies: photodynamic therapy, photothermal therapy and photoimmunotherapy.
Sanchez-Barcelo EJ, Mediavilla MD. Sanchez-Barcelo EJ, et al. Recent Pat Endocr Metab Immune Drug Discov. 2014 Jan;8(1):1-8. doi: 10.2174/1872214807666131229103707. Recent Pat Endocr Metab Immune Drug Discov. 2014. PMID: 24372346 Review.
Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders.
Sanchez-Barcelo EJ, Rueda N, Mediavilla MD, Martinez-Cue C, Reiter RJ. Sanchez-Barcelo EJ, et al. Curr Med Chem. 2017 Nov 20;24(35):3851-3878. doi: 10.2174/0929867324666170718105557. Curr Med Chem. 2017. PMID: 28721826 Review.
Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome.
Corrales A, Parisotto EB, Vidal V, García-Cerro S, Lantigua S, Diego M, Wilhem Filho D, Sanchez-Barceló EJ, Martínez-Cué C, Rueda N. Corrales A, et al. Among authors: sanchez barcelo ej. Behav Brain Res. 2017 Sep 15;334:142-154. doi: 10.1016/j.bbr.2017.07.022. Epub 2017 Jul 23. Behav Brain Res. 2017. PMID: 28743603
Constitutive photomorphogenesis protein 1 (COP1) and COP9 signalosome, evolutionarily conserved photomorphogenic proteins as possible targets of melatonin.
Sanchez-Barcelo EJ, Mediavilla MD, Vriend J, Reiter RJ. Sanchez-Barcelo EJ, et al. J Pineal Res. 2016 Aug;61(1):41-51. doi: 10.1111/jpi.12340. Epub 2016 Jun 13. J Pineal Res. 2016. PMID: 27121162 Review.
Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome.
Parisotto EB, Vidal V, García-Cerro S, Lantigua S, Wilhelm Filho D, Sanchez-Barceló EJ, Martínez-Cué C, Rueda N. Parisotto EB, et al. Among authors: sanchez barcelo ej. Neurochem Res. 2016 Nov;41(11):2904-2913. doi: 10.1007/s11064-016-2008-8. Epub 2016 Jul 23. Neurochem Res. 2016. PMID: 27450081
63 results
Jump to page
Feedback